Hospital for Special Surgery (HSS) ranked No. 1 in Orthopedics and No. 3 in Rheumatology by U.S. News & World Report.
ByAinvest
Tuesday, Jul 29, 2025 12:08 am ET1min read
Hospital for Special Surgery (HSS) has been ranked No. 1 in the nation for orthopedics for a 16th consecutive year and No. 3 in rheumatology by U.S. News & World Report. HSS was evaluated based on patient outcomes, nursing care, patient experience, and technology. The hospital has maintained low readmission rates for orthopedics and has provided specialized care to over 248,917 patients in 2024. HSS clinicians performed over 43,000 orthopedic surgical procedures in the same year.
Hospital for Special Surgery (HSS), the world's leading orthopedic health system, has announced a collaboration with Abridge to enhance clinical documentation, communication, and care outcomes. This strategic partnership leverages Abridge's AI platform to revolutionize the way orthopedic care is documented and managed.HSS, known for its excellence in orthopedics, has maintained its top ranking for the 16th consecutive year by U.S. News & World Report. The hospital, which serves over 248,917 patients annually, performed over 43,000 orthopedic surgical procedures in 2024. The collaboration with Abridge aims to further elevate the quality of care by integrating advanced ambient listening technology into the clinical workflow.
The Abridge AI platform is designed to capture clinical conversations in real-time, generating accurate and compliant documentation. This technology supports over 55 specialties and 28 languages, making it highly adaptable to the diverse needs of HSS's patient population. The platform automatically detects care settings, specialties, and languages, ensuring that the documentation is tailored to each specific scenario.
Dr. Ashis Barad, Chief Digital and Technology Officer at HSS, expressed enthusiasm about the collaboration, stating, "Ambient scribing was just the beginning. With Abridge’s foundational AI expertise alongside our orthopedic leadership, we can dramatically elevate clinical note quality, communication, and ultimately, care outcomes."
The upcoming orthopedic specialty documentation enhancements will focus on capturing detailed information about imaging, laterality, risks, and treatment options. This will result in clearer documentation, improved coding precision, and more efficient clinical workflows. Dr. Shiv Rao, CEO and Co-Founder of Abridge, noted, "We are going a million miles deep on each specialty and care setting to deliver documentation that works as both the perfect clinical artifact and compliant note."
The collaboration between HSS and Abridge is a significant step forward in transforming orthopedic care. By leveraging AI technology, the partnership aims to reduce administrative burden, improve clinician efficiency, and enhance patient outcomes. The integration of Abridge's AI platform into HSS's clinical processes aligns with the hospital's commitment to innovation and excellence in musculoskeletal health.
References:
[1] https://finance.yahoo.com/news/hospital-special-surgery-selects-abridge-130000419.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet